Novartis’ AveXis doubles down with $115M manufacturing investment

SourceFierce Pharma
Date Published02/19/2019
Author NameEric Palmer
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name AveXis
Parent companyNovartis
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):200
Year reshoring announced:2019
Year reshoring implemented or to be implemented:2020
Capital investment ($):115
Country(ies) from which reshored:Switzerland
City reshored to:Durham
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredgene therapy
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Lead time/Time to market, Skilled workforce availability/training
Government Incentive dollar amount:1.4
Find Reshoring Articles